JP2014177455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014177455A5 JP2014177455A5 JP2014043175A JP2014043175A JP2014177455A5 JP 2014177455 A5 JP2014177455 A5 JP 2014177455A5 JP 2014043175 A JP2014043175 A JP 2014043175A JP 2014043175 A JP2014043175 A JP 2014043175A JP 2014177455 A5 JP2014177455 A5 JP 2014177455A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- kit
- cda
- substrate drug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026846 Cytidine deaminase Human genes 0.000 claims 13
- 108010031325 Cytidine deaminase Proteins 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000000758 substrate Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 229960003603 decitabine Drugs 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- AZYOZBIYZJGKSO-XKBRQERYSA-N 4-amino-1-[(2r,4s,5s)-5-[fluoro(hydroxy)methyl]-4-hydroxyoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](C(O)F)[C@@H](O)C1 AZYOZBIYZJGKSO-XKBRQERYSA-N 0.000 claims 1
- NGGRGTWYSXYVDK-RRKCRQDMSA-N 4-amino-5-chloro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 NGGRGTWYSXYVDK-RRKCRQDMSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 1
- 229950006410 tezacitabine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98039707P | 2007-10-16 | 2007-10-16 | |
| US60/980,397 | 2007-10-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530110A Division JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014177455A JP2014177455A (ja) | 2014-09-25 |
| JP2014177455A5 true JP2014177455A5 (enExample) | 2015-02-05 |
| JP5859588B2 JP5859588B2 (ja) | 2016-02-10 |
Family
ID=40251685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530110A Active JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
| JP2014043175A Active JP5859588B2 (ja) | 2007-10-16 | 2014-03-05 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530110A Active JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
Country Status (39)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| US8846628B2 (en) | 2008-05-15 | 2014-09-30 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US20100055047A1 (en) * | 2008-08-26 | 2010-03-04 | Yiyu Zou | Methods for treating bronchial premalignancy and lung cancer |
| NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| JP5684787B2 (ja) * | 2009-04-06 | 2015-03-18 | 大塚製薬株式会社 | シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用 |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| JO3262B1 (ar) * | 2009-04-06 | 2018-09-16 | Otsuka Pharma Co Ltd | توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان |
| AR076262A1 (es) * | 2009-04-06 | 2011-06-01 | Eisai Inc | Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| KR20200060782A (ko) | 2013-01-31 | 2020-06-01 | 길리애드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| ES2712877T3 (es) | 2013-10-29 | 2019-05-16 | Otsuka Pharma Co Ltd | Ruta sintética de 2-desoxi-2,2-difluorotetrahidrouridinas |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| LT3182996T (lt) | 2014-08-22 | 2023-03-10 | Celgene Corporation | Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais |
| CA3007357C (en) * | 2015-12-03 | 2023-12-05 | Epidestiny, Inc. | Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof |
| WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
| AU2019216531A1 (en) | 2018-02-02 | 2020-09-24 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
| JP2021535395A (ja) * | 2018-08-28 | 2021-12-16 | エッセンリックス コーポレーション | アッセイ精度向上 |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| CN112888700B (zh) * | 2018-10-19 | 2025-03-04 | 因特欧力多公司 | 具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物 |
| JP7433662B2 (ja) | 2018-10-19 | 2024-02-20 | インターオリゴ・コーポレイション | 治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物 |
| US12187757B2 (en) * | 2019-10-08 | 2025-01-07 | Otsuka Pharmaceutical Co., Ltd. | 2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same |
| IL294288A (en) * | 2020-02-25 | 2022-08-01 | Otsuka Pharma Co Ltd | Solid oral dosage forms in combination with decitabine and cadazuridine |
| AU2022244240A1 (en) * | 2021-03-26 | 2023-10-05 | The Cleveland Clinic Foundation | Treatment of rna virus infection with a cytidine deaminase inhibitor |
| US20240279266A1 (en) * | 2021-05-29 | 2024-08-22 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds |
| AU2022370354A1 (en) | 2021-10-19 | 2024-05-30 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
| WO2023076332A1 (en) * | 2021-11-01 | 2023-05-04 | St. John's University | Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor |
| US20230271996A1 (en) * | 2021-12-25 | 2023-08-31 | Scinopharm Taiwan, Ltd. | Process for preparing cedazuridine |
| WO2024047394A1 (en) | 2022-08-31 | 2024-03-07 | Otsuka Pharmaceutical Co., Ltd. | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017606A (en) * | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
| US4210638A (en) * | 1978-03-17 | 1980-07-01 | Pcr, Inc. | Antiviral composition and method of treating virus diseases |
| US4275057A (en) | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| WO1985001871A1 (en) | 1983-10-26 | 1985-05-09 | Greer Sheldon B | Method and materials for sensitizing neoplastic tissue to radiation |
| DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US4965374A (en) | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| WO1992018617A1 (en) | 1991-04-23 | 1992-10-29 | Oglevee, Ltd. | In vitro leaf petiole multiplication of pelargoniums |
| FR2682112B1 (fr) | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
| US5594124A (en) | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
| US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
| DE69403588T2 (de) | 1993-02-23 | 1998-01-22 | Hope City | 4-ethoxy-5-fluor-2'-deoxyuridine |
| AU6081294A (en) | 1993-05-14 | 1994-12-12 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
| US5637688A (en) | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
| WO1996026743A1 (en) * | 1995-03-01 | 1996-09-06 | Human Gene Therapy Research Institute | Radiation enhanced gene therapy for treatment of tumors |
| US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
| US5760208A (en) | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
| US6933287B1 (en) | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
| DK1156827T3 (da) * | 1999-03-01 | 2007-02-05 | Halogenetics Inc | Anvendelse af sammensætninger omfattende CldC som strålingssensibilisatorer ved behandlingen af neoplastiske sygdomme |
| EP1207783A1 (en) | 1999-08-26 | 2002-05-29 | Aortech International PLC | Improvements relating to catheter positioning |
| US6462191B1 (en) | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
| EP1348712B1 (en) | 2000-11-29 | 2011-05-04 | Mitsui Chemicals, Inc. | Processes and intermediates in the synthesis of L-thymidine |
| WO2002056912A2 (en) | 2001-01-16 | 2002-07-25 | Glaxo Group Limited | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
| US7589077B2 (en) | 2001-05-18 | 2009-09-15 | Rakesh Kumar | Antiviral nucleosides |
| EP1418949B1 (en) * | 2001-07-31 | 2013-06-19 | THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF OREGON | Inhibitor of dna methylation |
| US20040002476A1 (en) | 2002-02-14 | 2004-01-01 | Stuyver Lieven J. | Modified fluorinated nucleoside analogues |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| EP1545558A4 (en) | 2002-09-24 | 2010-02-17 | Koronis Pharmaceuticals Inc | 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES |
| WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US8158770B2 (en) | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
| US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
| WO2006015346A1 (en) | 2004-07-30 | 2006-02-09 | Pharmaessentia Corp. | STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES |
| JP2007522151A (ja) | 2004-12-08 | 2007-08-09 | シコール インコーポレイティド | ジフルオロヌクレオシド及びその調製方法 |
| WO2008085611A2 (en) * | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
| WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
| JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
| AR076262A1 (es) | 2009-04-06 | 2011-06-01 | Eisai Inc | Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer |
| JO3262B1 (ar) | 2009-04-06 | 2018-09-16 | Otsuka Pharma Co Ltd | توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان |
| JP5684787B2 (ja) | 2009-04-06 | 2015-03-18 | 大塚製薬株式会社 | シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用 |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
-
2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en not_active Ceased
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active Active
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 RS RS20120232A patent/RS52323B/sr unknown
- 2008-10-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
-
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
-
2012
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
-
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
-
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
-
2023
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-26 FR FR23C1052C patent/FR23C1052I2/fr active Active
- 2023-12-26 FR FR23C1051C patent/FR23C1051I2/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown
- 2023-12-27 NL NL301257C patent/NL301257I2/nl unknown
- 2023-12-29 LT LTPA2023539C patent/LTPA2023539I1/lt unknown
- 2023-12-29 LT LTPA2023538C patent/LTC2207786I2/lt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014177455A5 (enExample) | ||
| DK3826632T3 (da) | Terapeutiske sammensætninger, der omfatter deutererede eller delvist deutererede n,n-dimethyltryptaminforbindelser | |
| JP2013518107A5 (enExample) | ||
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| JP2015078230A5 (enExample) | ||
| JP2014221779A5 (enExample) | ||
| JP2016521119A5 (enExample) | ||
| JP2011500713A5 (enExample) | ||
| MX382221B (es) | Compuestos de fórmula iv para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae | |
| JP2017524735A5 (enExample) | ||
| EA201592075A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| MX389802B (es) | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos. | |
| JP2016508134A5 (enExample) | ||
| UA99476C2 (en) | 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors | |
| JP2014507446A5 (enExample) | ||
| HK1213018A1 (zh) | 橋接雙環核苷 | |
| JP2016540015A5 (enExample) | ||
| JP2011527299A5 (enExample) | ||
| JP2017518250A5 (enExample) | ||
| CN109863160A (zh) | 核苷磷酸类化合物及其制备方法和用途 | |
| HUE060752T2 (hu) | Korrózióvédõ készítmény, amely tartalmaz legalább egy elsõ vegyületet és legalább egy második vegyületet | |
| JP2011518153A5 (enExample) | ||
| PH12015502589A1 (en) | 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives | |
| JP2016540019A5 (enExample) | ||
| EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды |